Hong Kong biotech: from niche exposure to broader product ecosystem

Hong Kong has quickly transitioned from a listing venue for biotech firms into a market with a growing suite of biotech products and derivatives. This expanding product ecosystem is deepening liquidity and enabling more sophisticated ways to access and manage biotech exposure.

Biotechnology is rapidly becoming one of Hong Kong’s most dynamic growth sectors, driven by China’s expanding capacity for novel drug development, a surge in licensing activity and supportive policy reforms.

Mainland China firms’ share of licensing deals in biopharma – a biotech subsector – with upfront payments above US$50 million, rose from 5% in 2022 to 50% in the first quarter of 2026.

The total value of biotech licensing deals is expected to double again over the next 18–24 months, according to Bank of America Securities, as global drug manufacturers search for China-developed experimental medicines ahead of patent expirations. This momentum is accelerating the sector’s shift from early-stage research to commercialisation and global relevance – with Hong Kong playing a crucial role.

Since 2018, listing reforms and an expanding suite of investment tools have transformed Hong Kong into a premier global hub for biotech financing. At the centre of this transformation sits the Hang Seng Biotech Index (HSBIO).

Launched in 2019, the index supports a biotech investment ecosystem spanning equities, exchange-traded funds (ETFs), single stock options and structured products. The Hong Kong Stock Exchange (HKEX) also launched HSBIO Futures in November 2025, providing a new tool for accessing the fast-growing China biotech market.

From niche theme to established sector

HSBIO’s recent performance has drawn global investor attention to Hong Kong’s biotech sector. The index climbed more than 64% in 2025, outpacing the Hang Seng Index, which rose around 28%.¹

This outperformance has dispelled the perception that HSBIO is dominated by speculative, pre-revenue companies. Although many constituents listed as pre-revenue, most now generate revenue and have shed the ‘B’ designation – the HKEX marker used to identify pre-revenue biotech companies.

As of May 2026, only four members remained pre-revenue, representing around 4% of index weight. Hong Kong’s biotech sector now comprises more than 270 listed companies with a combined market capitalisation over HK$4 trillion.

That maturation is also reshaping how investors trade the sector. Biotech performance is often driven by discrete catalysts, clinical trial readouts and regulatory decisions – and China’s expanding clinical pipeline is increasing the frequency of those milestones.

In 2024, China listed more than 7,100 trials in the World Health Organization’s International Clinical Trials Registry Platform, compared with about 6,000 in the US.

“HSBIO reflects the overall performance of the 30 largest biotech and pharmaceutical companies listed in Hong Kong. It is designed to capture the full lifecycle of biotech innovation – from research and development-led companies to those with established commercial products,” says Candy Lam, executive director, head of product at Hang Seng Indexes Company.

“As the sector matures, the index naturally reflects that progression while maintaining strict liquidity, market capitalisation and market accessibility criteria. This index methodology ensures that, as start-ups evolve into revenue-generating enterprises, HSBIO’s composition shifts to include companies with real earnings alongside the next generation of drug developers. HSBIO is designed to be accessible under Southbound Stock Connect eligibility and, with a growing range of index-linked products, is also becoming a more accessible benchmark for biotech exposure, supporting the continued development of the index-linked product ecosystem,” says Lam.

Complementing Hong Kong equity benchmarks

Compared to broader indexes such as the Hang Seng (HSI), Hang Seng China Enterprises (HSCEI) or the Hang Seng TECH Index (HSTECH) – collectively known as ‘other Hang Seng indexes’ – HSBIO offers diversification through uncorrelated growth drivers.

In practice, HSBIO’s biotech focus results in materially less exposure to the mega-cap stocks that dominate HSI, HSCEI and HSTECH, broadening the opportunity set beyond traditional large-cap concentration.

HSTECH is a flagship for China’s tech sector and tends to move with economic cycles, earnings trends and global macro sentiment. HSBIO, by contrast, trades on biotech-specific milestones. Investors that want to rotate between tech and biotech now have dedicated tools to do so, allowing more precise thematic allocation.

From a risk perspective, HSBIO exhibits higher volatility than broader large-cap indexes, with annualised volatility of around 30% as of May 2026.² This largely reflects the event-driven nature of the biotech sector, where company performance is often shaped by outcomes of clinical trials or regulatory decisions.

Much of this volatility is idiosyncratic rather than market-wide, and its relatively low correlation with major indexes can make HSBIO a useful portfolio diversifier.

Biotech exposure can add diversification, not just more of the same risk.

On a one-year daily return basis,³ HSBIO’s correlation to the HSI is 0.59⁴ and is lower still versus other Hang Seng indexes, whereas the other three major benchmarks each show correlations above 0.91. In practice, this offers meaningful diversification within Hong Kong equities.

Expanding the biotech product ecosystem

A deep and active product ecosystem has developed around HSBIO, spanning cash equities, ETFs, structured products and derivatives.

There are 13 ETFs tracking HSBIO listed in Hong Kong and mainland China, with combined assets under management reaching HK$12.2 billion as of May 2026. In parallel, the number of biotech-linked structured products has risen sharply, supporting tactical positioning and yield strategies linked to the sector.

A major milestone came in late 2025 with the launch of HSBIO Futures. This development closed a critical gap, replacing reliance on correlated proxies with a direct capital-efficient tool for hedging and trading biotech exposure.

Together, these products create a virtuous cycle for liquidity. Arbitrage and hedging between stocks, ETFs and futures help tighten pricing, support market-making activity and improve market efficiency across the biotech ecosystem.

“As the ecosystem has expanded, we’ve seen meaningful improvements in secondary market liquidity,” observes Max Lan, head of ETF investment at ChinaAMC (HK). “The availability of different product types – from ETFs to futures – means a wider range of investors can take part. This, in turn, reinforces trading volumes and tightens spreads across the board. ChinaAMC (HK) is honoured to have played an active role in building out this ecosystem, and we see it as both a responsibility and an opportunity to help deepen this market.

“With HKEX’s listing reforms cementing Hong Kong as the main venue for innovative Chinese biotech companies, our ChinaAMC Hang Seng Biotech Index ETF – the first of its kind to focus exclusively on Hong Kong‑listed names – gives local and mainland investors broader access to the innovation pipeline driving the growth of China’s healthcare sector.”

Institutional use of futures

For institutional market participants, futures often serve multiple purposes.

One is hedging: fund managers can now hedge biotech stock or ETF holdings against sector-wide risks.

Futures also support market-making and arbitrage. ETF issuers and market-makers use futures to hedge ETF creations/redemptions and to arbitrage differences between the futures price and the index’s fair value. This keeps ETF pricing in line and liquidity flowing.

Interconnected products – such as cash equities, ETFs and derivatives – help deepen liquidity by enabling arbitrage, hedging across instruments and improving pricing efficiency.

Biotech ETF turnover has risen alongside the introduction of futures, with bid/ask spreads continuing to narrow. HSBIO Futures has also traded, with spreads of around 15 basis points in May 2026, tighter than those of the underlying 30-stock basket.

The expanded product suite also strengthens price discovery, as futures, ETFs, structured products and underlying stocks increasingly inform one another’s pricing.

If a major development occurs overnight, for example, it may be reflected in the futures’ price during the extended trading session. This would then provide a reference for index movements at the next market open, particularly given the event-driven nature of the biotech sector.

Biotech comes of age

In just a few years, Hong Kong has cultivated a multi-asset biotech offering that mirrors the sector’s evolution. HKEX now provides a comprehensive biotech investment platform spanning biotech listings, ETFs, structured products and a futures contract for risk management.

For investors, the question may no longer be whether biotech belongs in portfolios, but how best to access and manage that exposure. In this context, biotech is evolving from a niche theme into a core component of Hong Kong’s capital markets.

_{1 Past performance is not indicative of future results
2 Bloomberg
3 April 30, 2025–April 30, 2026
4 Bloomberg, correlation calculation period: May 31, 2025–May 31, 2026}
 

Learn more

Biotech at HKEX

Sponsored content